All relevant data are within the manuscript and its Supporting Information files.

Introduction {#sec001}
============

A tissue-specific autoimmune disease process starts decades before the clinical onset of autoimmune diseases, such as rheumatoid arthritis (RA) \[[@pgen.1008788.ref001]\]. Most likely the first trigger involves the activation of autoreactive T cells, which are normally regulatory or anergic, into a more aggressive state. The activation requires strong costiumulation, which during an immune response is mediated by adjuvants carried by infectious organisms or possibly damaged endogenous cells, or environmental hazards such as tobacco smoke \[[@pgen.1008788.ref002]\]. These challenges trigger the innate immune system, leading to the activation of autoreactive T cells. Innate immune cells interpret infectious intruders or danger signals *via* a range of pattern-recognizing receptors (PRRs) on their cell surfaces. When the innate cells sense enhanced risk in the environment, these cells are able to activate other cells, such as T cells. If the activation of adaptive responses displays joint specificity, the situation could initiate clinical arthritis. Animal models of arthritis mimic these disease stages \[[@pgen.1008788.ref003]\]. They are initiated by adjuvant immunization followed by an autoimmune response to a tissue-specific protein. In the case of collagen-induced arthritis (CIA), it is the type II collagen (CII) that is involved and in the case of arthritis induced by various type of adjuvants, such as pristane-induced arthritis (PIA), or mineral-oil induced arthritis (OIA), a bystander response is raised to a pattern of unknown endogenous auto-antigens \[[@pgen.1008788.ref004]\]. Clinical arthritis starts to develop 2 weeks after the injection, as a result of an inflammatory attack on peripheral cartilaginous joints, involving the autoimmune response, that later can develops into a chronic inflammatory disease.

To determine the basic mechanisms leading to an autoimmune disease we searched for the genetic polymorphisms that allow the development of disease in certain inbred strains. For our investigation, we selected a cross between the DA rat, which is highly susceptible to autoimmune diseases, and the disease resistant E3 rat strain. The rats were injected intra-dermally with pristane, a simple alkene adjuvant oil which triggers a disease that fulfils the classification criteria for RA \[[@pgen.1008788.ref005]\]. Through genetic linkage mapping, we identified 20 arthritis-associated loci in the DA rat \[[@pgen.1008788.ref006]\]. One of the major loci was localized to chromosome 4 and was denoted *Pia7*. The same locus was identified using several different arthritis models, including CIA, PIA and OIA \[[@pgen.1008788.ref007]--[@pgen.1008788.ref009]\]. With the use of recombinant congenic strains, the disease association could be mapped to a gene family encoding C-type lectin receptors, denoted hereafter as APLEC (antigen presenting cell expressing lectin like receptor gene complex) \[[@pgen.1008788.ref010],[@pgen.1008788.ref011]\]. APLEC contains a cluster of 8 genes, 4 of which have a carbohydrate recognition domain highly similar to the full-length *Clec4a/Dcir and* are thus denoted *Clec4a1-3*. The complex also covers 4 non-*Dcir* like C-type lectins: *Clec4b2b/Dcar*, *Clec4d/MCL*, *Clec4e*/*Mincle* and *pClecn*/*Dectin2* (a non-functional pseudo-gene in both the DA and E3 strains). It has been proposed that both *Clec4a* and *Clec4b* are important in antigen presentation and uptake \[[@pgen.1008788.ref012],[@pgen.1008788.ref013]\] as well as in T cell responses \[[@pgen.1008788.ref014]\] and can be assumed to be of importance early in an immune response. Furthermore, there is a genetic association to human DCIR in RA \[[@pgen.1008788.ref015]\]. In contrast, *Clec4d* and *Clec4e* are involved in later inflammatory responses \[[@pgen.1008788.ref016]\]. We have now located a single nucleotide polymorphism (SNP) in the *Pia7* locus, regulating the *Clec4b* gene. Only E3 derived cells express the Clec4b/Dcar receptor and it is expressed on CD4^+^ Dendritic cells. The loss of *Clec4b/Dcar1* expression leads to dysregulation of CD4^+^ myeloid antigen presenting cells, which lose the ability to control bystander activation of autoreactive T cells. This previously unknown physiological regulator of autoreactive T cells, are of critical importance to the development of autoimmune disease.

Results {#sec002}
=======

A SNP within the *Clec4b* gene explain the arthritis-association {#sec003}
----------------------------------------------------------------

The DA.E3-*Pia7* congenic strain is less susceptible to arthritis compared to the DA strain \[[@pgen.1008788.ref011]\]. We chose to fine map the underlying polymorphisms within the Pia7 locus for association with arthritis using OIA, which gives a milder arthritis compared with PIA. In fact, the same locus as Pia7 has also been mapped in OIA and designated Oia2 \[[@pgen.1008788.ref007]\]. We aimed to produce recombinant congenic strains to identify the experimental arthritis regulating polymorphism in Pia7. Whole-genome sequencing of both the DA and the E3 genomes was advantageous as it enabled us to identify at least 1 microsatellite marker/50 Kb within the APLEC region \[[@pgen.1008788.ref006]\]. More than 5000 pups were screened for recombination events using a panel of 37 microsatellite markers in the original 1.5 Mb DA.E3-*Pia7* interval. Two recombinant congenic strains were produced. The first identified sub-congenic strains, DA.E3-*Clec4a* contained arthritis protective E3 alleles only in the 4 *Clec4a* isoforms of the APLEC region where the recombination event occurred immediately after the Clec4a gene but before Clec4b2 between MS*Aplec*710 and MS*Aplec*740. The DA.E3-*Clec4bde* sub-congenic strain was the product of two separate recombination events, containing E3 alleles in *Clec4a*, *Clec4b2*, *Clec4d*, *Clec4e*, and the *Clec4n/Dectin2*, which is a pseudogene in both DA and E3 ([Fig 1A](#pgen.1008788.g001){ref-type="fig"}). Limited on the centromeric side by a recombination between MS*Aplec*573 and MS*Aplec*633 and distally by a recombination event occurring right after *Clec4e* between the markers D4rat90 and MS*Aplec*981.

![Identification of the arthritis-regulating gene in the *Oia2/Pia7/Cia13* locus on rat chromosome 4.\
a) An illustration of the distribution of the 8 C-type lectin genes across the APLEC interval on rat chromosome 4 and the congenic fragments with genomic regions harboring arthritis-susceptible DA alleles (grey) and arthritis-protective E3 alleles (black) for the three congenic strains DA.E3-*Pia7* to the far right, DA.E3-*Clec4a* to the left of the chromosome and DA.E3-*Clec4bde* to the far left. b) An illustration of the distribution of SNPs across the DA.E3-*Clec4bde* congenic fragment\[[@pgen.1008788.ref006]\] and the *Clec4bde* encoded genes, together with an illustration of the two non-synonymous SNPs and nearby SNPs in five different inbred strains including the reference rat strain BN. c) OIA development in DA strain and the 3 congenic strains. d) PIA development over time in the original DA strain and DA.E3-*Clec4bde* congenic. e) CIA development over time for the DA strain and the DA.E3-*Clec4bde* strain. Significance stars illustrate Mann. Whitney Test \* = *p\<0*.*05*, \*\* = *p\<0*.*01*, \*\*\* = *p\<0*.*001* \*\*\*\* = *p\<0*.*0001* and SEM. f) Gene expression of all APLEC encoded genes for DA and *Clec4b*^E3^ in naïve splenocytes. House-keeping gene is b2m and all genes are compared to one DA sample.](pgen.1008788.g001){#pgen.1008788.g001}

OIA assessment in the DA.E3-*Clec4a* strain showed no protection within this region, contrary to the full DA.E3-*Pia7* congenic strain ([Fig 1C](#pgen.1008788.g001){ref-type="fig"}). The sub-congenic strain DA.E3-*Clec4bde* on the other hand showed almost complete protection against OIA, as well as to PIA and CIA ([Fig 1C--1E](#pgen.1008788.g001){ref-type="fig"}). Sequencing the DA.E3-*Clec4bde* fragment identified two coding polymorphisms: a nonsense mutation in the DA strain that causes a truncated protein at exon two of *Clec4b2*; and a non-synonymous SNP in the membrane domain of *Clec4e* ([Fig 1B](#pgen.1008788.g001){ref-type="fig"}). The mouse has two isoforms of *Clec4b*; *Clec4b1* and *Clec4b2*. Since the rat only has the *Clec4b2* homolog we refer to this gene as *Clec4b*. The *Clec4d* gene was excluded as a candidate since it does not contain any coding or regulatory polymorphisms and does not show any differences in gene expression between strains ([Fig 1F](#pgen.1008788.g001){ref-type="fig"}). A comparison of the genome sequence with other inbred rat strains showed that the arthritis protective PVG and E3 share the same *Clec4bde* haplotype \[[@pgen.1008788.ref006]\], making them distinct from the DA *Clec4bde* haplotype. The arthritis protective F344 strain, on the other hand, have a *Clec4bde* haplotype that is identical to DA. When trying to identify strains that deviate in their *Clec4bde* haplotype, only 1 strain was different. The BN strain shares alleles with DA only in the *Clec4e* locus (see [Fig 1B](#pgen.1008788.g001){ref-type="fig"}), whereas the remaining sequence of the BN *Clec4bde* region is shared with E3, the arthritis protective haplotype. In a literature search to compare F2 crosses between DA and PVG, and between DA and BN strains, the arthritis quantitative trait locus at APLEC was reproduced in both crosses despite the arthritis susceptible version of *Clec4e* in BN. An APLEC arthritis QTL could not be reproduced in crosses between DA and the arthritis protective F344 strain, principally because F344 has the DA version of the full APLEC \[[@pgen.1008788.ref009]\]. The inherent ability to reproduce linkage in an F2 cross between DA and BN provided sufficient evidence to us to conclude that arthritis regulation most probably stems from variations in *Clec4b* rather than *Clec4e*. We identified a causative nonsense SNP in the *Clec4b* DA allele that causes a truncation of the DA allelic protein that is nonfunctional but with expressed transcripts. Thus, the DA strain is a natural functional knock-out for Clec4b, which further substantiates the gene as the arthritis regulating gene in the APLEC region. The two DA strains with different *Clec4b* alleles are hereafter denoted DA and DA.*Clec4b*^*E3*^, abbreviated as *Clec4b*^*E3*^ and occasionally \*E3. To investigate if other non-coding variations from the fragment could be regulatory, expression of all APLEC encoded genes were measured in DA and *Clec4b*^E3^ in naïve splenocytes. Only Clec4b showed differential expression ([Fig 1F](#pgen.1008788.g001){ref-type="fig"}). All raw data to figures are available in the [S1 Data](#pgen.1008788.s004){ref-type="supplementary-material"} file.

*Clec4b* is expressed in steady-state/immature CD4^+^ myeloid-derived spleen cells {#sec004}
----------------------------------------------------------------------------------

In order to identify possible mechanisms by which *Clec4b* could regulate experimental arthritis we first aimed to identify which cell types express the *Clec4b* gene. We analysed gene expression in blood, lymph nodes, thymus, bone marrow and spleen ([Fig 2A](#pgen.1008788.g002){ref-type="fig"}). The highest *Clec4b* expression was found in the spleen, but lower expression levels could also be observed in blood and lymph nodes. Bone marrow showed lower expression compared to spleen whereas no expression could be detected in thymus. *Clec4b* gene-expression was significantly down regulated in *DA* spleen compared to the *Clec4b*^*E3*^ strain.

![*Clec4b* expression is restricted to immature CD4+ myeloid cells in the spleen.\
a) Relative expression of *Clec4b* in five naïve immune-related tissue; spleen, blood, thymus, bone-marrow and inguinal lymph nodes (*n = 5* for spleen and thymus, remaining tissues *n = 3*). b) *Clec4b* expression of naïve spleen cells. The samples were pooled from three different spleens. Cells were first negatively selected for TCR, and then positively selected for CD4^+^ and CD8^+^ cells, respectively. After CD4/CD8 sorting, the remaining cells were selected for CD11b/c. Neutrophils were enriched from blood using Ficoll-Hypaque centrifugation. c) Non-pooled spleen samples were negatively selected for T cells and positively for CD4. The CD4- fraction is the flow-through cell (*n = 5*). d) Relative *Clec4b* expression in three naïve *Clec4b*^E3^ or one DA sample, all sorted with a Mo-flow FACS sorter. The FACS plot depicts the gating strategy for the three assessed population. Before CD4 and His24 (CD45R), the population determining gating, the cells were negatively sorted by gating for TCR and CD45RA, eliminating T cells and B cells. The cells were His24^-^ CD4^+^ (CD4+ DC), His24^-^ CD4^-^ (CD4^-^ DC) or His24^+^ CD4^+^ (pDCs) (*n = 3* for *Clec4b*^E3^ and *n = 1* for DA). e) Relative *Clec4b* expression in naïve and oil-primed splenocytes selected for TCR-CD4+ and for day 0, day 1 day 2, day 3, and day 5 after oil injection. *n = 5* for all groups. Significance stars depict Mann. Whitney Test \* *= p\<0*.*05*, *\*\* = p\<0*.*01*, *\*\*\* = p\<0*.*001* and SEM.](pgen.1008788.g002){#pgen.1008788.g002}

Next, we aimed to identify which splenic cell population expresses *Clec4b*. First, we pooled three naïve *Clec4b*^E3^ and three DA spleens and selected T cells and B cells using anti-pan-T and B cell labelled magnetic beads. The T and B cell negative flow-through was elected in two new magnetic labelled fractions, one for CD4^+^ and another for CD8^+^. The CD4^-^ flow-through was lastly also selected for CD11b/c^+^ cells. *Clec4b* expression was low in all cell types tested except for CD4^+^ T and B cell negative cells ([Fig 2B](#pgen.1008788.g002){ref-type="fig"}). Then unpooled individual magnetic bead selected splenocyte samples were assessed, *Clec4b* expression was significantly enriched in cells from *Clec4b*^E3^ compared to DA, and more than a tenfold increase in CD4^+^TCR^-^ compared to the CD4^-^TCR^-^ cells was observed ([Fig 2C](#pgen.1008788.g002){ref-type="fig"}). More than a sixtyfold difference in *Clec4b* expression was confirmed between CD4^+^ and CD4^-^ non-T/B cells when sorted with a flow sorter. This showed *Clec4b* expression exclusively in CD4+αβTCR^-^CD45RA^-^ (a B cell-marker) cells, whereas CD4^-^TCR^-^CD45RA^-^ had close to undetectable levels of *Clec4b* ([Fig 2D](#pgen.1008788.g002){ref-type="fig"}). Interestingly, plasmacytoid dendritic cells (pDCs) are known to be CD4^+^ in the rat, and to determine if pDCs also express *Clec4b* we used a previously established rat pDC sorting protocol \[[@pgen.1008788.ref017]\] followed by gene-expression assay. Lower levels of *Clec4b* were observed in pDCs, albeit without any strain difference ([Fig 2D](#pgen.1008788.g002){ref-type="fig"}). A recent study by Daws et al \[[@pgen.1008788.ref018]\] supports both of these findings, suggesting that rat Clec4b is highly expressed in CD4^+^ myeloid cells but not in CD4^+^ pDCs.

The fact that OIA is a rapid arthritis disease model, with an onset of clinical arthritis within 10--12 days of injection, suggests that disease regulating genes are already operating within the first few days of injection. In order to examine changes in the kinetic expression of *Clec4b* during early arthritis-induction, CD4^+^ TCR^-^ bead selected splenocytes were isolated from both naïve animals and at different time points after mineral oil injection. The highest levels of *Clec4b* expression were observed in naïve splenocytes. A daily decrease in gene-expression was shown until day 5 after injection, when *Clec4b* levels were close to undetectable ([Fig 2E](#pgen.1008788.g002){ref-type="fig"}). This supports the argument that regulation of *Clec4b* expression is sensitive to rapid environmental changes, either transmitted by instant general immune responses to the oil injection. Alternatively, it indicates that the receptor is sensitive to the oil itself. The rapid downregulation of *Clec4b* after oil injection suggests that the C-type lectin receptor is expressed in naïve or steady-state DCs as a possible steady-state off-switch and that this signal could be important for accurate immune-activation.

The CD4^+^*Clec4b*^*+*^ cell population consists of two distinct subtypes, classical and granular/plasmacytoid dendritic cells {#sec005}
------------------------------------------------------------------------------------------------------------------------------

The *Clec4b* gene is expressed in CD4^+^ cells that are TCR^-^. CD4 is frequently expressed on pDCs in both rats and humans, \[[@pgen.1008788.ref017],[@pgen.1008788.ref019]\]. It has been suggested that CD4 is expressed on a subpopulation of conventional dendritic cells, cDC2 \[[@pgen.1008788.ref020]\] but this population is poorly characterized in the rat. Rat CD4^+^ DCs have been described as being better regulators of the MHCII^+^ Th1 adaptive responses than CD4^-^ DCs \[[@pgen.1008788.ref021]\], therefore, we wanted to investigate the phenotype and function of the CD4^+^TCR^-^ DC population. The CD4^+^*Clec4b*^+^ population was selected from naïve splenocytes with magnetic labelled pan T cell microbeads and, in the second step, with beads isolated TCR^-^CD4^+^ cells. The selected cells were then labelled with fluorescent antibodies and studied in a flow cytometer.

The yield from 100 x10^6^ splenocytes was 3.0 x 10^6^ ± 0.3 CD4^+^TCR^-^ cells and 26.1x 10^6^ ± 3.6 CD4^-^TCR^-^. More than 80% of the CD4^+^ selected fraction expressed CD4 and had less than 2% T cells ([Fig 3A and 3B](#pgen.1008788.g003){ref-type="fig"}). Within the CD4^+^ selected cell fraction, CD11b/c and the granulocyte marker His48 were expressed in noticeably differently patterns in different sub-populations ([Fig 3C](#pgen.1008788.g003){ref-type="fig"}). When the expression of major histocompatibility complex type II molecules (MHCII) was analysed in combination with forward scatter (FSC), three distinct populations were detectable, each representing a third of the total CD4^+^ pan T^-^ population ([Fig 3D](#pgen.1008788.g003){ref-type="fig"}). One population expressed high levels of MHCII, a second population expressed intermediate levels of MHCII, and a third population was found negative for MHCII. The MHCII^bright^ population showed classical dendritic cell characteristics, such as high CD11b/c and CD172 (Sirpα) expression and negative for the granulocyte marker His48 ([Fig 3E](#pgen.1008788.g003){ref-type="fig"}). The MHCII^dim^ population, on the other hand, was granulocyte-like with very high expression of His48. The population also expressed His24, one of the markers for pDCs, here defined by CD45RA^-^/TCR^-^/His24^+^/CD4^+^ expression \[[@pgen.1008788.ref017]\]. The MHCII^-^ population was more monocyte-like, expressing CD68 and CD11b/c at levels comparable to the MHCII^-^ population in CD4^-^TCR^-^, [S1 Fig](#pgen.1008788.s001){ref-type="supplementary-material"}. iNOS expression was elevated in both MHC expressing populations ([Fig 3E](#pgen.1008788.g003){ref-type="fig"}), from which one may infer that reactive nitrogen species are involved in shared regulatory functions. In conclusion, the *Clec4b* expressing CD4^+^ cells were shown to include two unique populations. The first is a dendritic cell-like population corresponding to the CD4^+^ classical DC subset that has been previously described in the rat spleen \[[@pgen.1008788.ref022]\], and which are similar to human cDC2. A second granulocyte-like population, which was undetected in the CD4^-^/*Clec4b*^*-*^ fraction and showed lower MHCII expression, corresponded to the pDC population. Since the pDC population was shown to express very low levels of *Clec4b* (see [Fig 2D](#pgen.1008788.g002){ref-type="fig"}), we conclude that the CD11b/c^+^ DC population should be the main *Clec4b* expressing CD4^+^ population in the spleen. The production of a monoclonal antibody for rat Clec4b is described in recently published data from Daws et al. \[[@pgen.1008788.ref018]\]. They also detailed how Clec4b is expressed mainly on CD4^+^ DC/monocytes \[[@pgen.1008788.ref018]\]. We found that Clec4b was only expressed in *Clec4b*^E3^ CD4^+^DCs but not in B or T cells ([Fig 3F](#pgen.1008788.g003){ref-type="fig"}). Comparing cellular expression of the Clec4b receptor showed significant differential expression between DA and DA congenic rats, expressing *Clec4b*^E3^ ([Fig 3G](#pgen.1008788.g003){ref-type="fig"}).

![*Clec4b* is expressed in CD4+ MHCII+ DCs in two distinct sub-populations that are either MHCIIhi classical dendritic cells or MHCIIdim pDCs.\
a) Frequencies of florescence labeled cells (n = 8 for all groups), first selected to be TCR-, and after a second sorting separated into either CD4^+^ or CD4^-^ fractions using a CD4 antibody coated beads. NK cells are CD161hi, Neutrophils are His48+ and CD11b/c+, pDC are CD4+ and (CD45R) His24^+^, B cells are CD45RA^+^ (OX33), CD11b/c cells are OX42^+^ and His48 cells are granulocytes. b-d) Antibody labeled cell frequencies for CD4^+^ and CD4^-^ fractions in the total mononuclear cell population. b) Shows CD4 and TCR (clone R73) expression. c) Expression of CD11b/c and His48. d) Illustrate MHCII^+^ expression (clone OX17) separated by cellular size by the forward scatter, and the three populations identified are also analyzed for each of the 8 samples and the cell frequencies are illustrated in a box-plot graph. e) Illustration of the cellular distribution based on antibody labeled fluorescence intensities for the three CD4^+^ subsets, classified by differential MHCII expression and cell size. The antibody expression frequencies described in the graphs are for the specific MHCII subsets. CD161^+^ population is actually CD161 intermediary and therefore is not describing NK cells which should be CD161hi. pDCs are CD4^+^ HIS24^+^. No strain comparisons for the CD4^+^ subsets showed any significant differences. f) Histograms describing anti-clec4b antibody staining in flow cytometer for either DA and *Clec4b*^E3^ splenocytes. Three gates are shown in the T cells, B cells, and the CD4^+^TCR- population. g) Mean fluorescence intensity for the Clec4b antibody illustrating expression per cell on the CD4^+^TCR^-^ population for both DA and *Clec4b*^E3^.](pgen.1008788.g003){#pgen.1008788.g003}

*Clec4b* deficient DA rats showed enhanced expansion of CD4^+^DCs at day 3 after oil injection. {#sec006}
-----------------------------------------------------------------------------------------------

With the intention of identifying how the non-sense mutations in the *Clec4b* gene affect the cellular immune response during the early phase of experimental arthritis, splenocytes were harvested from the first days after oil-injection and then studied by flow cytometry. Assessing the cellular distribution in naïve spleens did not show any differences in the composition of cell sub-set populations between DA and *Clec4b*^*E3*^ rats, [S2 Fig](#pgen.1008788.s002){ref-type="supplementary-material"}. However, three days after intradermal injection of arthritogenic oil we observed an increase of CD4^+^ myeloid cells in DA spleens, as measured *ex vivo* ([Fig 4A](#pgen.1008788.g004){ref-type="fig"}). Furthermore, the MHCII expressing subset of CD4^+^ DCs had expanded after activation and the difference between the two genotypes was more marked, discernible in the FACS plots ([Fig 4B](#pgen.1008788.g004){ref-type="fig"}). After day three, MHCII expression was two-fold in DA compared to *Clec4b*^E3^, and DA populations also showed enriched expansion of the adhesion molecule CD11b ([Fig 4C](#pgen.1008788.g004){ref-type="fig"}). On day three no differences were seen for either T or B cell subsets in the spleen, [S3 Fig](#pgen.1008788.s003){ref-type="supplementary-material"}. Populations of antigen-presenting cells were generally more activated in DA rats, so that there were more CD4^+^MHCII^+^CD80^+^ and CD4^+^MHCII^+^CD103^+^ cells ([Fig 4D](#pgen.1008788.g004){ref-type="fig"}). However, neither pDC nor monocyte populations expanded differentially between DA or *Clec4b*^E3^ during the first days of activation. Kinetic dissection of the early cellular responses to injection of an arthritogenic oil further supports dendritic cells as the cells initially involved in the *Clec4b* mediated responses and hence the arthritis development control.

![*Clec4b* is expressed in naïve CD4^+^ MHCII^+^ DCs that expand greatly in *Clec4b* deficient rats after activation and initiate the development of inflammatory dendritic cells.\
a) The kinetic distribution of CD4^+^ DCs (of TCR^-^ CD45+ cells) determined by flow cytometry in the spleen over time after IFA. n = 5 per group. Graph is a representation of 4 separate experiments. b) Kinetic distribution of geomean of fluorescence intensities of MHCII expression on CD4^+^ DCs over time after an intradermal IFA injection, and representative CD4 MHCII intensity plots for frequencies for samples from day 0, and day 4 after oil injection. Previously gated for TCR^-^ CD45^+^ cells. c) CD11b expression on TCR^-^ OX33^-^ MHCII^+^ cell as frequencies of total cells (*n = 5* per group). d) The distribution of DC subsets in spleen day 3 after oil injection. The displayed distribution is for total cells and is a representative sample from 3 separate experiments (*n = 5* per group). e) The relative expression of DC activation/differentiation regulating genes in the immune-precipitated CD4+ TCR- cells comparing expression day 0 to Day 3. Larger graph illustrates expression for both DA and *Clec4b*^E3^. Data from the two genotypes were pooled to give a general overview. The smaller upper graph describes relative gene expression for genes that were differentially expressed between DA and *Clec4b*^E3^. Significance stars depict Mann. Whitney Test *\* = p\<0*.*05*, *\*\* = p\<0*.*01* bars are for SEM (*n = 5* per group).](pgen.1008788.g004){#pgen.1008788.g004}

Aiming to delineate the expression differences in the CD4^+^ DCs, after oil injection, a set of DC-activation associated genes was compared by quantitative PCR between naïve cells and cells harvested three days after oil injection. CD4^+^ DCs at day three had increased gene expression of *IL12p40*, *Ifna*, CD4^+^DC activation marker *Ifr4*, and the pro-inflammatory regulator *Inos* suggesting an enhanced activated phenotype at day three. A comparison of DA to *Clec4b*^E3^ expression showed significantly higher expression of both *Inos*, and *Irf4* in DA. Furthermore, there was already a significant difference in *Stat1* expression between DA and *Clec4b*^E3^ in the naïve CD4^+^ myeloid cell population ([Fig 4E](#pgen.1008788.g004){ref-type="fig"}).

In summary, the DA CD4^+^ DC population expanded at day 3 compared to rats with *Clec4b*^E3^, displaying a distinct pro-inflammatory expression profile that promoted up-regulation and expansion of MHCII and adhesion markers such as CD11b. Thus, *Clec4b* deficiency lowers the threshold for classical CD4^+^ DC activation and MHCII expression.

*Clec4b* regulates activation of pro-inflammatory T cells before day five of OIA pathogenesis {#sec007}
---------------------------------------------------------------------------------------------

Adjuvant induced arthritis models in the rat, such as PIA and OIA, are mediated by arthritogenic auto-reactive T cells activated a few days after adjuvant injection (see [Fig 1C and 1D](#pgen.1008788.g001){ref-type="fig"}). Arthritogenic T cells can be isolated in draining lymph nodes as early as day 7 whereas the disease onset occurs around day 12 after adjuvant injection \[[@pgen.1008788.ref023]\]. To investigate the *Clec4b*-mediated regulation of auto-reactive T cells during OIA development and to identify the earliest time point by which T cells can transfer disease, we transferred bead selected T cells (98% purity) from rats primed with mineral oil IFA into naïve recipient rats. Sufficient T cell activation for mild joint swelling was seen already at day 5 after oil injection ([Fig 5A](#pgen.1008788.g005){ref-type="fig"}), whereas T cells from day 6 induced severe arthritis. Importantly, spleen T cells from DA but not DA.*Clec4b*^E3^ induced arthritis in naïve DA recipient rats. However, the presence of *Clec4b* in the recipient was irrelevant. As *Clec4b* is expressed in DC and not on T cells, these data demonstrates that *Clec4b* suppress T cell activation before day 5 during the immune response. Moreover, the absence of T cell regulation in *Clec4b* sufficient recipient rats shows that this early regulatory effect was absent after the T cell activation has advanced to autoreactive. T cells from draining lymph nodes transfer arthritis similarly to T cells from spleen ([Fig 5B](#pgen.1008788.g005){ref-type="fig"}).

![Arthritis transmitting T cells are induced already 5 days after oil injection.\
a) Transfer arthritis development in recipients after injection with 15 x 10^6^ spleen derived T cells from donor rats previously injected with mineral oil either 5 or 6 days beforehand. Donors and recipients are noted as d. and r. from either genotype; DA, or *Clec4b*^E3^(\*E3). *n = 5* for all groups. b) Transfer arthritis development in DA recipients after injection with 15 x 10^6^ T cells from inguinal lymph nodes taken from donor rats day 6 after oil injection (both groups *n = 5*). c) Day to day distribution of T cell subsets as frequencies of total cell (*n per time point = 5*). Statistical analysis was performed using Mann-Whitney Test *\* = p\<0*.*05* SEM. d) Day to day distribution of activation associated T cell markers as frequencies of total cells (*n per time point = 5*).](pgen.1008788.g005){#pgen.1008788.g005}

Since the T cells isolated at day 5 after oil injection were already arthritogenic, we sought to assess the *in vivo* primed T cells from day 0 by flow cytometry. As T cells from both sources transfer arthritis T cells \[[@pgen.1008788.ref023]\], subsets and activation markers were analyzed from both joint draining lymph nodes and splenocytes. Surprisingly, no expansion of CD4^+^CD25^+^ T cells was observed within the first 6 days after arthritis induction ([Fig 5C](#pgen.1008788.g005){ref-type="fig"}). However, a dramatic decrease of CD62L^+^CD4^+^ T cells among all live cells was seen in the spleen, from 15% to almost undetectable numbers at day two. This dramatic reduction of naïve T cells did not differ between the genotypes ([Fig 5C](#pgen.1008788.g005){ref-type="fig"}) but provides a clue that this population is downregulated immediately only hours after oil injection.

Co-cultures of CD4^+^ DCs and T cells identifies differential limiting effects on naïve T cell already 24hrs after stimulation {#sec008}
------------------------------------------------------------------------------------------------------------------------------

The CD4^+^DC subset is able to efficiently present antigen to T cells, and induce T cell activation \[[@pgen.1008788.ref021],[@pgen.1008788.ref024]\]. Since no clear population differences between DA and *Clec4b*^E3^ rats could be identified for T cells *in vivo* within the first six days after disease induction, T cell activation was evaluated during *in vitro* stimulation where proliferative responses can also be studied. Co-cultures were made to assess the CD4^+^DC regulatory function on T cell proliferation by labelling bead- selected T cells with CFSE. Moreover CD4^+^DC have been shown to be superior in stimulation of allogenic T cell responses in the rat compared to CD4^-^DCs. We harvested allogenic T cells from rats with the MHC haplotype RT1^u^, which differ from RT1^a^ in the DA rat, from both naïve rats and day three after IFA injection. Syngenic DA T cells were also harvested from day three after IFA, from both Cle4b^E3^ and DA rats. The different T cells were co-cultured with bead-selected CD4^+^DCs from either DA or *Clec4b*^E3^ in all combinations. Naïve allogenic T cells were co-cultured with naïve CD4^+^DCs, and the day three derived T cells, either allogenic or syngenic, were all co-cultured with day three *in vivo* derived CD4^+^DCs. Since arthritogenic T cells in the rat have been characterized as activated CD4^+^ T cells, proliferation was assessed in CD25^+^ CD4^+^ T cells \[[@pgen.1008788.ref023]\]. Proliferation was near 100% for both naïve and OIA day three harvested allogenic T cells however no difference in DC activation could be seen from *Clec4b*. This implies that *Clec4b* regulation on arthritogenic T cell development operates independent of MHCII. The CD4^+^DC mediated T regulation occurs, most likely, by limiting bystander activation via cytokine secretion. Interestingly, syngeneic *Clec4b*^E3^ derived T cells showed dramatically lower proliferation compared to DA. Since no effect could be seen for the two CD4^*+*^DCs populations in the co-cultures, the restricted proliferation seen for *Clec4b*^E3^ derived T cells must be due to regulatory differences during the first days *in vivo* rather than in the *in vitro* culture ([Fig 6A and 6B](#pgen.1008788.g006){ref-type="fig"}).

![*Clec4b* regulates CD4^+^ myeloid cell mediated suppression of naïve T cells in mixed lymphocyte reactions.\
a) Illustration of the gating for activated T cells, by first gating for live cells, then T cells, and CD4^+^CD25^+^ cells followed by proliferation as carboxyfluorescein succinimidyl ester (CFSE) low. And an illustration of CFSE histogram for two samples. b) Graph describes proliferation as CFSE low labeled CD4^+^CD25^+^ T cells from a) for Naïve or OIA Day 3 activated allogenic T cells and OIA Day 3 activated syngenic DA or *Clec4b*^E3^ T cells. The T cells have been co-cultured with OIA day 3 *in vivo* activated DCs from both genotypes, or cultured with naïve DCs from both genotypes (only for naïve allogenic T cells). c) *In vitro* stimulated *Clec4b* gene expression in CD4^+^ TCR- spleen cells, after 24 h culture with either Con A, TDM, mannan, CpG, LPS, complete media only (*n = 5* per group) Mann. Whitney Test *\*\* = p\<0*.*01* SEM. d) Comparisons of T cell subset in co-cultures mixing naïve DA T cells, cultured with Con A stimulated selected DCs, either CD4^+^DCs or CD4-DCs from DA or *Clec4b*^E3^. Frequencies of total cells are displayed for the co-culture at different DC:T cell ratios explained in 3 graphs; total CD4^+^ cells; total CD25^+^ CD4^+^ T cells; and proliferating (CFSE low) CD25^+^ CD4^+^ T cells. (*n = 10* for all groups) Mann Whitney Test *\* = p\<0*.*05*, *\*\* = p\<0*.*01*, *\*\*\* = p\<0*.*001* and SEM. e) Describes two four-way grouped co-culture experiments comparing the proliferative regulation from either DA or \*E3 (*Clec4b*^E3^) CD4^+^ DCs on bead selected CFSE labeled T cells from both rat strains and mixed in combinations in co-cultures for 72 h. n = 10 for all groups. 3 Graphs illustrate proliferative T cell subsets: total proliferating T cells, total CD4^+^ CD25^+^ T cells and the frequencies of proliferating CD4^+^ CD25^+^ T cells in all cells. Graphs describes regulation of proliferation on recently harvested naïve T cells by *in vitro* Con A activated CD4^+^DCs in different T cell to DC ratios/concentrations. Mann. Whitney Test *\* = p\<0*.*05*, *\*\* = p\<0*.*01*, *\*\*\* = p\<0*.*001* and SEM.](pgen.1008788.g006){#pgen.1008788.g006}

In order to find an appropriate stimulatory agent triggering down-regulation of *Clec4b* expression, known pro-inflammatory compounds (ConA, LPS, mannan, thiodimycholate and CpGs) were incubated with freshly isolated naïve spleen cells. Remarkably, there was downregulation of *Clec4b* expression already after 24h of ConA stimulation ([Fig 6C](#pgen.1008788.g006){ref-type="fig"}). However, there was no difference in viability of DCs after Con A between the two strains. Overnight ConA cultures activated naïve CD4^+^DCs cells to become strong inducers of T cell proliferation compared with CD4^-^DCs cells ([Fig 6D](#pgen.1008788.g006){ref-type="fig"}). This ability to induce proliferation of CD4^+^CD25^+^ T cells was unique to DA derived CD4^+^ DCs ([Fig 6D](#pgen.1008788.g006){ref-type="fig"}).

Endeavoring to assess the restraining ability on T cell activation/proliferation from *Clec4b*^E3^ derived DCs, two sets of DC:T cell co-cultures were prepared. Naïve Con A overnight activated CD4^+^DCs from DA and *Clec4b*^E3^ were combined with naïve T cells from either DA or *Clec4b*^E3^. Overnight ConA stimulation of CD4^+^DCs enabled the DCs from *Clec4b*^E3^ derived rats to limit proliferation of CD25^+^CD4^+^ T cells from either DA and *Clec4b*^E3^ equally efficiently after 72 hours of culture ([Fig 6E](#pgen.1008788.g006){ref-type="fig"}).

In summary, *Clec4b*^E3^ DCs from day 3 after oil injection failed to limit T cell activation in co-cultures with day 3 activated T cells, and T cell activation status correlated with the genotype of its origin ([Fig 6B](#pgen.1008788.g006){ref-type="fig"}). Naïve *Clec4b*^E3^ DCs, on the other hand, that had been ConA stimulated before co-culture with naïve T cells were able to inhibit activation and proliferation of T cells independent of the T cells *Clec4b* genotype ([Fig 6E](#pgen.1008788.g006){ref-type="fig"}). These data reveal that the arthritis regulating gene *Clec4b* expressed in CD4^+^ DCs can efficiently limit T cell activation in response to adjuvant/PRR stimulation, thus preventing the expansion of recently activated auto-reactive and potentially pathogenic T cells.

*Clec4b* in recipient naïve DCs regulates T cell proliferation on day four activated T cells *in vivo* after challenge by innate stimulus and down-regulation of IL17 production {#sec009}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Given the fact that only DA.*Clec4b*^E3^ and not DA derived T cells are prevented from the development into arthritogenic T cells after an intradermal injection of mineral oil, we propose that *Clec4b* should be able to allow DA donor T cell limiting responses *in vivo* after a second adjuvant injection in naïve recipients from the arthritis transfer model, as described in [Fig 5A and 5B](#pgen.1008788.g005){ref-type="fig"}. Since T cells have already become arthritogenic 6 days after arthritogenic oil injection, we investigated the activation and proliferation status of T cells transferred earlier than this time point. CFSE^+^ labeled T cells harvested from day 3 after oil primed DA rats were transferred to naïve DA.*Clec4b*^E3^ or DA rats. After transfering the primed T cells, the recipient was also challenged by an intradermal oil-injection to trigger the CD4^+^DCs. After 3 days in the recipients, the spleens were harvested and more than 30 million splenocytes were analyzed per sample by flow cytometer. 3 distinct population of T cells could be visualized in recipient spleens: an unlabeled population (CFSE^-^); a proliferative population (CFSE^low^); and a non-proliferating population (CFSE^high^) ([Fig 7A](#pgen.1008788.g007){ref-type="fig"}). Whilst the non-proliferating CFSE^high^ population corresponds to the main part of the donor T cell population, a considerable part of the donor CD4^+^ T cells (i.e. the CFSE^low^ population) were proliferating. Intriguingly, all cells in the CFSE^low^ subset were CD4^+^T cells, which corresponds well with previous findings from the Transfer arthritis model that has described the arthritogenic T cells as mainly CD4^+^\[[@pgen.1008788.ref023]\]. Since these donor T cells most likely have been exposed to a form of CD4^+^DC bystander activation of abundantly polyclonal antigen specificity, there will have been no definite starting point for the T cell proliferation. Thus, the CFSE density could not be visualized into distinct cell divisions. Therefore, we used a second proliferation marker (Ki67) to assess proliferation within the CFSE categories. Further analysis of donor T cells in the *Clec4b*^E3^ recipients revealed a significant regulation of the proliferating CD4^+^ T cells in terms of both cell expansion and activation (both lower KI67 and MHCII expression) ([Fig 7B and 7C](#pgen.1008788.g007){ref-type="fig"}). Conversely, no difference in activation and proliferation markers was detected in non-dividing (CFSE^high^) and endogenous T cells (CFSE^-^) between both congenic rats. Furthermore, the effects of polyclonal stimulation of transferred cells indicate a role of *Clec4b* in modulating IL-17 producing T cells on the basis that a reduction in IL-17^+^ dividing T cells frequency was found in *Clec4b*^E3^ compared to DA rats ([Fig 7D and 7E](#pgen.1008788.g007){ref-type="fig"}). However, no changes in the frequency of IFNγ^+^ T cells was detected. Notably, CFSE^high^ population failed to produce both IL-17 and IFNγ while endogenous T cells (CFSE-) produced IFNγ only. These findings corroborate the role of *Clec4b* in limiting T cell activation and proliferation *in vivo*. They also infer that *Clec4b* plays a part in controlling Th17 cells that together account for a substantial proportion of the DA susceptibility to adjuvant triggers that lead to arthritis development in the rat.

![*Clec4b* regulate T cell proliferation also *in vivo* and the activation correlate with down-regulation of IL17 production.\
DA rats were injected intradermally with oil and 4 days later the spleens were used as a source of oil primed T cells. These were CSFE labeled and injected intravenously into naïve DA and *Clec4b*^E3^ recipients that had been injected intradermaly with mineral oil the same day. a) Proliferation FACS plot describing CFSE intensity in CD4 versus CD8 T cells harvested from spleens of the recipients day 3 after oil injection. CFSE negative T cells are the recipient endogenous T cells. The CFSE^high^ are the non-proliferating T cells from the donors and the CFSE^low^ are the donor T cells that have been proliferating in the recipient. b) Histogram over the distribution of the three groups from a and how they differ in the expression of both Ki67 and MHCII on their surface. c) Graphs describing how the two donor groups, non-dividing and dividing T cells, differ in the expression of MHCII and Ki67 between DA and *Clec4b*^E3^ recipients. d,e) Illustration on how the expression of the two cytokines IFNg and IL17 is distributed between the three groups of differentially proliferating T cells between the Clec4b sufficient and deficient recipient rats. d) Illustrative FACS plot. e) Statistics analysis and graph. n = 4 for all groups, Mann Whitney Test *\* = p\<0*.*05*, *\*\* = p\<0*.*01*, *\*\*\* = p\<0*.*001* and SEM.](pgen.1008788.g007){#pgen.1008788.g007}

Discussion {#sec010}
==========

The identification of a single nucleotide polymorphism controlling the expression of *Clec4b* in the rat highlights a new role of *Clec4b* in regulation of autoreactive T cell activation. The suggested identification of the *Clec4b* SNP to be causative was based different type of evidence. Firstly, it was found within a 200kb chromosomal interval defining the QTL Pia7. This genomic region harbors three protein coding genes, whereof two had non-synonymous SNPs. Of these, only the SNP in *Clec4b* showed functional evidence as it led to differential gene expression in naïve rats. Secondly, data from several genetic mapping studies aiming to identify arthritis susceptibility regulating loci in the rat, shows that only the DA version of Clec4b segregates with disease susceptibility, and not strains lacking the *Clec4b* SNP but maintaining the polymorphism outside the *Clec4b* locus. Thirdly, only the DA *Clec4b*.*E3* congenic, and not the DA rat, expresses the Clec4b protein. More specifically, Clec4b is highly expressed on CD4+ DCs, a population known to be regulating MHCII interaction and T cell activation. Interestingly after an intradermal oil injection, the DA strain displays a rapid onset of autoreactive T cells whereas *Clec4b*.*E3* rats have normal control of T cell activation after oil injection. *Clec4b* is a C-type lectin receptor, expressed in classical CD4^+^DCs, and we now find that it is essential for the control of bystander activation of autoreactive T cells during immune priming. Deficient expression of *Clec4b* allows the escape and expansion of autoreactive T cells leading to arthritis.

T cells from a rat strain deficient in *Clec4b* expression are able to transfer arthritis to naïve rats already 5 days after being activated by adjuvants. Two-photon imaging of DC T cell interactions *in vivo* has revealed that, after adjuvant stimulation, T cells quickly attach to the activated DCs via interaction with peptide-loaded MHCII that then leads to T cell viability decisions within the first 12 hours \[[@pgen.1008788.ref025]\]. Our data suggest that *Clec4b* is a regulator of these viability decisions and thereby helps to prevent T cells from responding to self-peptides that are already present on classical DCs and vulnerable to activation. It is suggested that immature/steady state DCs have a tolerogenic function during steady-state \[[@pgen.1008788.ref026]\]. During pattern recognition, receptor-mediated activation of DCs will occur at a critical time point when these self-presenting DCs need to differentiate or die in order to prevent development of autoimmunity \[[@pgen.1008788.ref027]\]. We suggest that Clec4b function is a control switch for the tolerogenic DCs to either transform or die during the short interval when the DCs have received secondary inflammatory signals, yet are still capable of activating T cells directed to an immunogen that are, in most cases, derived form a pathogenic intruder. We have identified two triggers of Clec4b, mineral oil and Con A, which will activate DCs lacking Clec4b expression, leading to uncontrolled T cell proliferation. The presence of the lectin receptor Clec4b/Dcar on the DC surface cause a more controlled activation of DC with Clec4b^E3^, compared with DC with Clec4b^DA^, inducing less expression of proinflammatory genes such as Stat1, Irf4 and iNos, that could limit bystander T cell activation.

Importantly, mature T cells that possess a variable degree of self-reactivity and have escaped negative selection---through low avidity or by the absence of the relevant tissue antigens during their selection---can potentially cause autoimmune disease \[[@pgen.1008788.ref028],[@pgen.1008788.ref029]\]. During the first priming immune response there are multiple mechanisms leading to activation of T cells with high affinity to peptides derived from the invading pathogen or immunogen. In the same time period, however, other cells with variable degree of self-reactivity need to be suppressed. We have now identified a way in which such autoreactive T cells can be suppressed by dendritic cells expressing Clec4b during a limited period during the immune priming. If Clec4b is not functioning properly, autoreactive T cells could be activated that could be pathogenic and cause an autoimmune arthritis that mimics rheumatoid arthritis.

The CD4^+^ DCs population in the rat spleen have previously been described to be highly efficient inducers of MHCII restricted T cell activation and to express enhanced levels of co-stimulatory receptors \[[@pgen.1008788.ref022]\]. These also express PRRs on their surface \[[@pgen.1008788.ref021]\]. A possible mouse counterpart to the rat CD4^+^ DC is CD11b^+^ CD8a^-^DC, which have been described as a mediator of peripheral tolerance via MHCII \[[@pgen.1008788.ref030]\]. Targeting antigen bound antibodies to a steady-state associated C-type lectin receptor DEC-205 without antigen can induce tolerance in mice \[[@pgen.1008788.ref031], [@pgen.1008788.ref032]\]. In the mouse, there are two isoforms of *Clec4b* and of these *Cle4b2* could have a different function as it is expressed on CD8^+^ DC and involved with cross-presentation to MHCI of peptides circulating in the early endosome \[[@pgen.1008788.ref013]\]. Instead, the less homologous isotype *Clec4b1* (DCAR2) could be functionally more similar to rat Clec4b as it is co-expressed with *Clec4a4* (DCIR2) \[[@pgen.1008788.ref033]\] on mouse CD8^-^ CD11b^+^ DCs, the mouse splenic DC subset analogous to the rat CD4^+^ DCs. *Clec4a4* was recently identified as a mediator of inflammation and MHCII:T cell immunity because both its function and the DC specificity show similarities with the identified function of rat *Clec4b* \[[@pgen.1008788.ref014],[@pgen.1008788.ref034]\]. However the proportion of CD4^+^ and CD8^+^ dendritic cell populations differ between rats and mice where rat DCs better resembles human DC subsets \[[@pgen.1008788.ref035]\]. However, rat Clec4b most likely does not have a completely overlapping set of functions with human CLEC4C, since the latter is a human pDC bio-marker \[[@pgen.1008788.ref036],[@pgen.1008788.ref037]\] and Clec4b fails to show significant expression in rat pDCs.

*Clec4b* expressing CD4^+^ DCs plays an important role in limiting the expansion of autoreactive T cells during an immune response and, in particular, when the immune response is triggered in the absence of strong antigens. This new role of antigen-presenting DCs is of fundamental importance in understanding autoimmune diseases but may also have important implications for current explanations of the lack of autoreactive T cell responses in growing tumors.

Methods {#sec011}
=======

Selective breeding of congenic animals {#sec012}
--------------------------------------

DA/ZtmRhd (DA.RT1^Av1^) and E3/ZtmRhd (E3) were originally obtained from Zentralinstitut fur Versuchstierkunde (Hannover, Germany) but maintained as inbred strains in our laboratory for more than 20 generations. The original 2.3Mb DA.E3-*Pia4* congenic strain was produced and back-crossed to DA for at least 16 generations\[[@pgen.1008788.ref011]\]. Two recombinant congenic strains were produced by marker-assisted selective breeding from back-crossed DA.E3-*Pia4* heterozygotic parents in an F2 inter-cross. During the process of producing the recombinant strains the congenic strains were back-crossed to DA three more times. The DA.E3-*Clec4a* recombinant was obtained after 567 meiosis and occurred between MSaplec710 and MSaplec740 (which is downstream of *Clec4a* before *Clec4b2*. DA.E3-*Clec4bde*) was produced from intercrossed DA.E3-*Pia4* in two steps. The first recombination occurred between MSaplec573 and MSaplec633 upstream of *Clec4a* and happened after 1723 meiosis. The second recombination in the DA.E3-*Clec4bde* fragment occurred after 4831 meiosis between D4Rat90 and MSaplec1003 right after the *Clec4e gene*. The congenic fragment DA.E3-*Clec4bde* is a 340 kb congenic fragment between164.61 Mb to 164.95 Mb on chromosome 4 conformed to the Baylor Rn4 2004 assembly and is illustrated in the schematic in [Fig 1A](#pgen.1008788.g001){ref-type="fig"}. Markers for the production of the two subcongenic strains were: From the distal top D4MIR55F GCTGAGTTTTGGGGTTGATTT, D4MIR55R GGTACAGCCGCCTTCTT, D4WOX49F TGATCTCAGCACCCATGTAA, D4WOX49R GCAGGACAGCCAGGACTAC, MSaplec573F ACCAGTAAACACCATCATTGG, MSaplec573R CACATTGATGAAAGGCACAA, MSaplec637F CACTTCCCAGACAAAGTTGC, MSaplec637F AGGTACAATGGCACACACCT, MSaplec710F CTTCTATTACTTAACATCATTGCCATA, MSaplec710R GGGTCAAACTGCCAGATAAA, MSaplec740F AGTAATGCCCCATGTGAAAA MSaplec740R GACCTGCATGCACATGAATA D4RAt90F CTCAGCATGCTCGCCACT, D4RAt90R TGTTATGACACTGTCTTATGGTGAA, MSaplec981F TGCACCTGAGCATGTAAGTGTAT, MSaplec981R CCTGAACAGTCCTGACATAAACC.

Allogenic rats were congenic DA.RT1^u^. Animals were maintained at the Scheele Laboratory, in the Karolinska Institutet, in a pathogen-free environment according to the Federation of European Animal Laboratory Science Association guidelines (FELASA). All procedures and animal experiments have been approved by the local ethics committee (Stockholms djurförsöksetiska nämd). The animals were maintained in a 14h light and 10h dark cycles and held individually in cages containing wood shavings and aspen. Moreover, they had free access to water and were fed with the standard rodent chow.

Arthritis experiment {#sec013}
--------------------

Arthritis was elicited by a single intradermal injection at the dorsal side of the tail base. For PIA induction, 150 μl pristane (2,6,10,14-tetramethylpentadecane, 95%; Acros Organics, Morris Plains, NJ, USA) was injected. For induction of OIA, 200 μl mineral oil (incomplete Freund's adjuvant /IFA/, BD, Franklin Lakes, NJ, USA) was injected. For induction of CIA, rat collagen type II (CII), dissolved in 0.1*M* acetic acid and emulsified in IFA, was injected. All used rats were \>8 weeks old. All experiments were performed with littermate rats that were age-matched, distributed within the cages and blind evaluated by the investigator. The rats were regularly inspected, including monitoring the limbs for arthritis development by a previously described macroscopic scoring systems. Briefly, 1 point was given for each individual swollen and erythematic toe and up to 5 points for an inflamed ankle (15 points in total per paw) \[[@pgen.1008788.ref038],[@pgen.1008788.ref039]\]. The scoring was carried out every second or third day for 20--30 days after disease induction. No points were given to deformed paws that did not exhibit signs of inflammation.

For transfer OIA, we harvested spleens or inguinal lymph nodes. Concisely, at day 6 or day 5 post injection organs were made in to single cell suspension. T cells were positively selected using magnetic CD6 Macs beads. Cells were then culture for 56 hours in complete media and stimulated with 10 μg/ml αTCR (R73) and 5 μg/ml αCD28 (JJ319) and later injected into recipient naïve rats. Cells from DA or *Clec4b*^E3^ were injected into DA or *Clec4b*^E3^ recipients and arthritis development was monitored using a 0--60 macroscopic scoring system. All experiments follow established guidelines involving littermate controls, mixing of groups in cages and blinded scoring evaluation.

Cell preparation and immuno-sorting {#sec014}
-----------------------------------

Splenocytes were harvested from naïve spleens 1--5 days after oil injection. Single cell suspensions were prepared as follows. Inguinal joint draining LNs and spleens were harvested from euthanized rats and digested for 30 min at 37°C with 1 ml digestion buffer (1 mg/ml collagenase IV, Sigma-Aldrich, St. Louis, MO, USA) in DMEM media (Sigma-Aldrich), Spleens were passed through 40-μm cell strainers and washed twice in sterile PBS. Red blood cells were lysed by adding 2 ml of ACK buffer (155 mM NH~4~Cl, 10 mM KHCO~3~ and 0.1 mM EDTA) to the pellet. After incubation for 3 mins at 4--8°C, lysis reaction was stopped by adding cold PBS, centrifuged (8 min, 300*g*) and washed in ice-cold PBS.

Immuno-precipitation of samples in single cell suspensions was performed according to the manufacturer's protocol (Miltenyi biotec. Gladbach, Germany). T cells were selected using OX52 (CD6) Macs beads. T cell negative fractions were harvested from the flow-through. The T cell-purity was never less than 97%, the non-T cell flow-through had less than 3% contaminant T cells. The non-T cells flow-through was used for sorting the CD4+ non-T cell fraction using Macs CD4+ beads (coated with OX38). CD8+ or CD11b/c+ non-T cells were selected by using streptavidin-coated Macs beads coupled to biotin conjugated anti-CD8 antibodies (clone OX8, BD Franklin Lakes, NJ, USA) or CD11b/c+ (clone OX42, Biolegend San Diego, CA, USA). B cells were selected from single cell suspensions using CD45RA coated Macs beads (Clone OX33). Neutrophils were selected from EDTA-treated whole blood. First from this selection were PBMCs isolated by 6% dextran and centrifugation, followed by neutrophils isolated using Ficoll Hypaque, according to *Current Protocols in Immunology 7*.*23*.*1*.

Gene expression {#sec015}
---------------

RNA was extracted from -80C snap frozen tissue samples using RNAeasy (Qiagen, Hilden Germany). cDNA was prepared by reverse transcriptase (iScript Bio-Rad Hercules, CA, USA) and qPCR amplification was performed using iq-SYBR green supermix (Bio-Rad Hercules, CA, USA). To eliminate potential splicing effects two different primer sets that cover different regions of the *Clec4b* gene were used in the tissue and cell type-characterizing experiment. The amplified sequence was cloned and sequenced for both primer sets and both sets were verified to have amplified *Clec4b* specific sequences and neither of the highly similar other APLEC encoded receptors. All other genes show gene expression from 1 primer set amplicon.

Clec4b2:1F TGCTCATCTGTTGGTGATCCA, Clec4b2:1R TGTAAAATAACCCCAACGAGTGTCTA, Clec4b2:2F AAAACTGCCCCAAGGTAAGG, Clec4b2:2R GAAGCAGGTGCTGAGGAGTAA, Clec4e.F TTTCACAGAGTCCCTGAGCTTCT, Clec4e.R TCCCTCATGGTGGCACAGT, Clec4d.F CACAAGGCTAACATGCATCCTAGA, Clec4d.R GCAAAGTAACAGTTAGACTGGAATGCT, Clec4a1F CATTCGTCCGTGGAAGACAAA, Clec4a1R TGCAGAGTCCCTGGAAGT, Clec4aF CCATAGCAAGGAAGAACAGGACTT, Clec4aR TGAATCCCAGAGCCCTATAAAATAA, Clec4a2F TCCTTGGGCACCTACTCAGAA, Clec4a2R GGAACCTGGCTTACTTGGATGA,Clec4a3F AGCCAGGAAGAGCAGGATTTC, Clec4a3R TGATCGACCCATTGCCATT IRF1F CCATTCACACAGGCCGATAC, IRF1R TCCTCGATGTCTGGTAGGGA, IRF2F ACAACACTTACACCTTGCGG, IRF2R GCATGGTACCCTCTCAGTGT, IRF4F GCCAACCCAGGTTCATAACT, IRF4R TGACTGGTCAGGGGCATAAT, IRF7F TCTGGATGAAGCTGATGCAC, IRF7R CCTCTGGGGGTGGTAAGTT, IRF8F CCCGAGGAAGAGCAAAAAA, IRF8R TCAGCTCCTCGATCTCTGAA, IkarosF GCCACAACTACTTGGA, IkarosR GCTGTGGTTAGTTTCTTCCTTAATGA, IL10F CCCTCTGGATACAGCTGCG, IL10R GCTCCAGTCCCTTGCTTTTATT, IL23_F AAAAGTGACGTGCCCCGTAT, IL23R GCAAACAGAACTGGCTGTTG, IL12p40F AGCAGCAGTTCCCCTGAGTCT, IL12p40R GGCACGCCACTGAGTACTTCT, Stat1F CCACAACTGTCTGAAGGAGGA, Stat1R TCACGGTGTTCTGAATATTTCC, IFNaF CAGCAGATCCTCAGCCTCTT, IFNaR TGCTGCTGGAGGTCATTACA, Nos2F GGAGCGAGTTGTGGATTGTT, Nos2R GGGAAGCCTCTTGTCTTTGA, GapdhF TCAACTACATGGTCTACATGTTCCAG, GapdhR TCCCATTCTCAGCCTTGACTG, B2MF CGTGATCTTTCTGGTGCTTGTC, B2MR TTCTGAATGGCAAGCACGAC, TBPF AGAACAATCCAGACTAGCAGCA, TBPR GGGAACTTCACATCACAGCTC, PpiaF ATTCATGTGCCAGGGTGGTG, PpiaR GGACCTGTATGCTTCAGGATG,

All quantifications were based on the Livak method 2-ddCT and minimum one of 3 housekeeping genes PPIA, Gapdh, TBP, or beta-2-macro.

Flow-cytometry {#sec016}
--------------

Cells in single-cell suspension were added to 96-well V-bottom polypropylene plates (BD Falcon) at 10^6^ cells/well and incubated with saturating concentrations of mAbs (see below). Cells were washed with FACS buffer and incubated in BD Cytofix/Cytoperm for 20 mins at room temperature and washed twice in BD Perm/Wash before staining with Abs to CD68. Fluorescence minus one control were used in all experiments. Dead cells were stained with Live/Dead Violet (Invitrogen) after washing the cells twice in Dulbecco's PBS without sodium azide and FCS. A SORP BD LSR II analytic flow cytometer (BD Biosciences) was used for acquisition and the data were analyzed with FlowJo (Tree Star). The following Alexa Fluor 488--, PE-, PerCP-Cy5.5--, allophycocyanin-, allophycocyanin-Cy7--, Qdot-655--, and biotin-conjugated Abs were used for flow cytometry: 2.4G2/BD Fc Block (CD32), OX-8 (CD8a), OX-1 (CD-45), HRL-1 (CD62l) and WT.5 (CD11b) were purchased from BD Pharmingen (San Diego, CA); R73 (αβTCR), OX-62 (CD103), W3/25 (CD4), 24F (CD86), 3H5 (CD80) purchased from BioLegend (San Diego, CA USA); OX-39 (CD25), OX-17 (RT1-D), His24 (CD45R/B220), His36 (ED-2) were purchased from eBioscience (San Diego, CA); and ED1 (CD68), purchased from AbD Serotec.

Co-culture assay {#sec017}
----------------

Splenocytes from either naïve- or oil-injected rats were prepared in single cell suspension and selected with antibody coated beads, either in a negative or positive selection for the following surface receptors: CD4^+^ CD6^-^ (CD4^+^ DCs), CD4^-^CD6^-^ (CD4^-^ DCs) or CD6^+^ (total T cells) as previously described. Cells were cultured in complete DMEM media (10% FCS, 1M Hepes (Sigma, St Louis, MO, USA), 50 uM 100U/ml penicillin, 100 ug/ml streptomycin, 50 uM β-mercaptoethanol (Sigma St Louis, MO, USA)). *In-vitro* stimulation of naïve CD4^+^ DCs was prepared in 24-hour cultures of complete media in addition to one of the following: 3ug/ml Concanavalin A (Sigma, St Louis, MO, USA); 5 ug/ml Trehalose Dimycolate (TDM)(Sigma, St Louis, MO, USA); 10 ug/ml Mannan (Sigma, St Louis, MO, USA); 50 ug/ml CpG-A 1668 (Invivogen, San Diego, CA, USA) or 3 ug/ml LPS (Sigma, St Louis, MO, USA). For proliferation assays magnetic-bead selected T cells were labeled with CFSE 2 uM before 72 hrs culture in complete media with either *in vivo* activated CD4^+^ DCs taken from day one, day two or day three of after oil injection or CD4^+^ DCs activated *in vitro* for 24 hours with Con A.

*In vivo* proliferation assay and cytokine ELISA {#sec018}
------------------------------------------------

T cells were harvested from four DA rats at day four after oil injection. T cells were harvested from whole spleen and lymph nodes and selected using magnetic CD6 Macs beads and subsequently labeled with CFSE. The labeled T cells where then immediately injected to naïve rats from either the DA or *Clec4b*^E3^ strain. T cells from one rat from day four oil injected donors, were split between one DA and one *Clec4b*^E3^ recipient. The naïve recipients where then challenged with an intradermal injection of oil and, three days later, spleens and draining lymph nodes were collected. The cells were labeled with antibodies to CD3, MHCII and CD25 in order to measure expression together with CFSE from the donor T cells. More than 100 million cells where assessed per recipient animal using a flow cytometer. Other cells were cultured with PMA, ionomycin and brefeldin A for 6 hours and further stained intracellularly with anti-IL17, IFNg and IL10 antibodies and analyzed with the flow cytometer.

Ethics statement {#sec019}
----------------

All animal experiments were approved by the local ethics committee (Stockholms djurförsöksetiska nämd) and all experiments were carried out according to method approved (Ethical Approval Number N35/16). Animal anesthesia was performed using an inhalant gas mixture of isoflurane and air. All euthanasia was carried out using CO^2^ gas.

Supporting information {#sec020}
======================

###### Illustration of cell population subsets within both the CD4+ as well as the CD4- fraction of antigen presenting cells depending on their expression of MHCII.

Three spleens harvested from day 3 after oil injection were selected first for T cells were the negative fraction was collected and selected a second time for CD4 expression. The twice selected cells were either CD4^+^ or CD4^-^, each represented as 3 samples. The samples were then labeled with fluorescence conjugated antibodies to identify subsets of cells. Since there appeared to be 3 clear subsets of CD4+ DCs depending on the MHCII expression the cells were first gated as either MHCII negative, MHCII high/bright and MHC dim. The value on the x axis is the present of total number of cells.

(TIF)

###### 

Click here for additional data file.

###### Illustration of cell subsets in the naïve spleen of DA versus *Clec4b*^E3^.

(TIF)

###### 

Click here for additional data file.

###### Illustration of distribution of B and T cell subset in the spleen of DA versus *Clec4b*^E3^ at 3 days after oil injection.

(TIF)

###### 

Click here for additional data file.

###### Excel-file that includes data to all graphs for the figures in this manuscript.

The file have 1 sheet per figure where the different subset graphs in each figure are named by their index.

(XLSX)

###### 

Click here for additional data file.

We thank Michael Daws and Erik Dissen for providing the Clec4b antibody. We also thank our animal house technicians Carlos and Kristina Palestro for their tremendous help in maintaining the animals.
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14 Sep 2019

Dear Dr Holmdahl,

Thank you very much for submitting your Research Article entitled \'Positional cloning of Clec4b - a novel regulator of bystander activation of auto-reactive T cells and autoimmune disease\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the current manuscript that need to be addressed. Based on the reviews, we will not be able to accept this version of the manuscript, but we would be willing to review again a much-revised version. We cannot, of course, promise publication at that time.

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer. We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see our [guidelines](http://journals.plos.org/plosgenetics/s/submission-guidelines#loc-materials-and-methods).

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

Derry C. Roopenian

Associate Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: Bäckdahl et al perform positional cloning and suggest a polymorphism in Clec4b confers resistance to arthritis in rats. They find that Clec4b is primarily expressed in CD4+ dendritic cells (DCs) and that mice carrying the susceptibility allele show an increased activation of CD4+ DCs upon stimulation. They then attempt to demonstrate, using both in vitro and in vivo assays, that the resistance allele in DCs suppresses T cell activation.

I have three major concerns:

1 -- The authors never perform a complementation assay to prove that Clec4b is responsible for the phenotypes observed. This needs to be addressed experimentally.

2 -- Although the authors present various in vitro and in vivo assays, it is not clear that the biological effects observed are intrinsic to DCs. This can be addressed with the following series of in vitro experiments. (1) T cell responses from both strains of mice can be stimulated in vitro. This will allow to unequivocally determine whether the alleles impact T cell responses. (2) DCs from both strains should be cultured in vitro with naïve allogeneic T cells. This will allow to determine if the alleles expressed in DCs impact T cell activation.

3 - The authors often mention the suppressive effect of the resistance allele on DC function. It is not clear how the assay was designed to truly monitor suppression of T cell activation as opposed to a decrease in T cell activation. A true suppression assay must be performed to claim suppressive activity.

Minor comments:

The nomenclature for designating DC should potentially be revised in line with the recent designations. I believe that the authors are referring to a subset of cDC2, namely CD4+ cDC2. It is not clear why the authors avoid using the recent nomenclature.

References are missing to support the first statements in the introduction.

Figure 2 -- There are white and black bars in the figure. It is not clear what these represent.

Why is it unexpected that the Clec4b is less expressed in the DA mice carrying the stop codon?

Figure 2b. The relative expression of Clec4b in B cells and T cells is not shown.

Figure 6. It is mentioned that the DCs suppress T cell activation. Is it truly suppression or lack of activation?

Figure 6. The data presented in panel D is very difficult to interpret. According to the labelling in the figure, the greatest effect seems to come from the genotype of the T cells. This contrasts with the information written in the text.

Panel 6E is mentioned in the text, but is not present in the figure.

The y axes in figure 7C appear to be non-linear. The interpretation of the data is difficult.

There are numerous grammatical and syntax errors throughout. In addition, the nomenclature is sometimes erroneous, not uniform, or not standard. For example, CD11bc should read CD11b/c; snps are usually abbreviated as SNPs; cells were not sorted -- they were selected with magnetic beads; etc. The text and figures need to be carefully revised.

Reviewer \#2: This is an interesting study where the authors describe the possible identification of a new rat autoimmune arthritis gene and suggest a mechanistic explanation. While the findings are of potential interest there are several issues in the study that were not clear, including assumptions attributed to a gene that was not clearly studied, and therefore lacked mechanistic specificity. Here are my comments including major and minor ones:

Given that the locus on chromosome 4 was identified in PIA and the congenics were protected in PIA (figure 1) it was not clear why the authors used the milder OIA to fine map the region.

More details about the breeding of the congenics should be provided as it is not clear how many generations were backcrossed and whether contaminating E3 fragments elsewhere in the genome were in fact excluded (this is critical in this study). What markers were used in the breeding?

The Clec region had been previously implicated in OIA by Lorentzen et al. In this study the authors tried to refine that association. Clec4b was implicated as the disease gene in the 200kb interval primarily because E3 and BN shared the same allele, while DA and BN had the same Clec4e allele. However, there is a co-localizing locus in a DAxF344 intercross and in congenics, and DA has the same alleles as F344 at both gene SNPs as reported in figure 1B. That raises concern about whether this is in fact the gene accounting for arthritis effect, or whether there is another gene elsewhere (E3 contamination). Additionally, it was surprising to see the authors exclude the intergenic and intronic SNPs at Clec4b, Clec4d and Clec4d simply because they were not in coding regions, particularly given that it is now known that those distant elements may regulate gene expression. Therefore, it appeared to me that there was not enough evidence to implicate only the coding SNP in Clec4b and exclude the others.

It was also surprising that the only "functional data" that really relates to Clec4b were mRNA levels. The authors should have shown changes in Clec4b protein levels (none is shown despite extensive flow cytometry looking at other proteins), or protein function, or protein localization in the plasma membrance, or in signaling pathways specifically regulated by Clec4b, or that knocking down Clec4b affected a phenotype. But none of that was shown and therefore the implication of Clec4b in the CD4+APC-regulated behavior appeared speculative. How do the authors think that Clec4b in APCs would regulate autoreactive T cell development/proliferation?

Unclear why authors use two different nomenclatures to refer to the E3 congenics: please choose one.

In addition to spleens, it would have been interesting to know whether the synovial tissue expression of the Clec genes differed between DA and congenic.

The authors should comment on whether the Clec region has been associated with rheumatoid arthritis or other autoimmune diseases in humans.

APC and DC appear to be used interchangeably in the manuscript which was a little confusing and could be changed.

Results, section 4, paragraph 2: reference figure 3c but in fact should be figure 4e.

Results, section 5, last paragraph: CD62L data not shown and it is not clear what the authors think of those results.

ConA has been shown to induce murine macrophage apoptosis: did the authors check for that? Is it possible that macrophages from the two strains differed in susceptibility to apoptosis and that was the difference in mediating T cell responses?

How is ConA affecting Clec4b expression, and how is Clec4b interfering with autoreactive T cell development and/or responsiveness?

The authors used the term 'positional cloning' in the title, but then refer to the SNP as 'arthritis-associated' in the results: please clarify.

It was not clear which strain was studied in figure 3 but it would be interesting to see a comparison between both strains.

There were also several minor text typing errors.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: No: The data is plotted in bar graphs showing mean and SD. It would be best if the data points were shown. Some of the representative flow cytometry profiles are missing.

Reviewer \#2: No: breeding strategy and markers used were not provided.

some flow cytometry mentioned in the manuscript was also not shown.

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

10.1371/journal.pgen.1008788.r002
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\* Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. \*

Dear Dr Holmdahl,

Thank you very much for submitting your Research Article entitled \'Positional cloning of Clec4b - a novel regulator of bystander activation of auto-reactive T cells and autoimmune disease\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important topic but identified some aspects of the manuscript that should be improved. 

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

Editors comments:

The manuscript still needs to be heavily edited for English grammar, etc, and the typos in Figures fixed as noted by the reviewers.

"Positional cloning" is an inexact term that only partially describes your efforts.  You used high resolution mapping to narrow a candidate genomic region.  This was followed by sequence analysis to identify a most probable SNP in Clec4b, followed by functional studies to test that contention. 

As noted in the reviews, the evidential support that Clec4b is responsible for the phenotypes is indirect without complementation or some other direct test.  We suggest that you you temper the interpretations and conclusions in that regard. What you have accomplished is to provide a several lines of indirect support for your contention, importantly including new data with the anti-Clec4b antibody (Fig 3F).  

In addition we ask that you:

1\) Provide a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

2\) Upload a Striking Image with a corresponding caption to accompany your manuscript if one is available (either a new image or an existing one from within your manuscript). If this image is judged to be suitable, it may be featured on our website. Images should ideally be high resolution, eye-catching, single panel square images. For examples, please browse our [archive](http://www.plosgenetics.org/article/browse/volume). If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License. Note: we cannot publish copyrighted images.

We hope to receive your revised manuscript within the next 30 days. If you anticipate any delay in its return, we would ask you to let us know the expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments should be included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, you will need to go to the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

Please let us know if you have any questions while making these revisions.

Yours sincerely,

Derry C. Roopenian

Associate Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: The authors addressed some of my concerns by providing additional data supporting the view that Clec4b contributes to autoimmunity. However, a complementation assay was not performed.

Some of the text still needs revision. This needs to be corrected by an English-speaking editor.

It is so difficult to read at times that I am not sure I understand the experimental approach.

Here are some examples (please don\'t limit your corrections to these few examples).

Therefor (needs an e)

\"When developing tissues specificity\" This is in the intro. It is not clear what is meant here.

A few sentences start with \"Suggesting\". This needs to be corrected.

Supernatant usually does not contain cells. Do the authors mean \"flow through\"?

effects vs affects

A sentence starts describing figure 6 with \"Most likely\" - this sentence structure needs to be revised.

Capital letters are used inappropriately in words in mid-sentence.

etc\...

Reviewer \#3: The manuscript entitled \"Positional cloning of Clec4b - a novel regulator of bystander activation of auto-reactive T cells and autoimmune disease\" proposed that Clec4b is a novel regulator expressed in CD4+ DCs and limit T cell activation. Although the authors did not clearly address the molecular mechanism mediated by Clec4b, the identification of candidate polymorphism by positional cloning is significant. To confirm the role of Clec4b directly through genetical approaches, the authors may want to perform CRISPR/Cas9-mediated complementation in DA rats and/or introduction of the same mutation in E3 rats.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#3: No: The mRNA expression of each Clec would be better to be shown as ∆∆Ct.

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#3: No

10.1371/journal.pgen.1008788.r004
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18 Mar 2020

\* Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. \*

Dear Dr Holmdahl,

Thank you very much for submitting your Research Article entitled \'Identification of Clec4b as a novel regulator of bystander activation of auto-reactive T cells and autoimmune disease\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important topic but identified some aspects of the manuscript that should be improved.

While we continue to believe that this study deserves communication by *PLOSgenetics*, consistent with the reviewers previous comments, we believe that definitive causality of the Clec4b missense SNP continues to be overstated in the revised manuscript. 

In Abstract: "We have positionally cloned a non-sense loss of function single nucleotide polymorphism in the C-type lectin receptor, Clec4b, and have shown that it controls chronic autoimmune arthritis in rat models of rheumatoid arthritis. "

In Introduction: "We have now located the causative single nucleotide polymorphism (SNP) in the Pia7 locus where it functions in regulating the Clec4b gene."

In Discussion: (1st para) "The identification of a single nucleotide polymorphism controlling the expression of Clec4b/Dcar in the rat has been found to be of major importance for the regulation of autoreactive T cell activation and the development of arthritis."  

The 1^st^ paragraph of the discussion would be a good place to rationalize why the you consider the SNP to be the likely cause of the QTL. 

We ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made.

In addition, we suggest that you again have the manuscript edited for its grammar.

In addition we ask that you:

1\) Provide a detailed list of your responses and a description of the changes you have made in the manuscript.

2\) Upload a Striking Image with a corresponding caption to accompany your manuscript if one is available (either a new image or an existing one from within your manuscript). If this image is judged to be suitable, it may be featured on our website. Images should ideally be high resolution, eye-catching, single panel square images. For examples, please browse our [archive](http://www.plosgenetics.org/article/browse/volume). If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License. Note: we cannot publish copyrighted images.

We hope to receive your revised manuscript within the next 30 days. If you anticipate any delay in its return, we would ask you to let us know the expected resubmission date by email to <plosgenetics@plos.org>.

You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, you will need to go to the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

Please let us know if you have any questions while making these revisions.

Yours sincerely,

Derry C. Roopenian

Associate Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

10.1371/journal.pgen.1008788.r006
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22 Apr 2020

Dear Dr Holmdahl,

We are pleased to inform you that your manuscript entitled \"Identification  of Clec4b as a novel regulator of bystander activation of auto-reactive T cells and autoimmune disease\" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional accept, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at <plosgenetics@plos.org>.

In the meantime, please log into Editorial Manager at <https://www.editorialmanager.com/pgenetics/>, click the \"Update My Information\" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about one way to make your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Derry C. Roopenian

Associate Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

[www.plosgenetics.org](http://www.plosgenetics.org)

Twitter: \@PLOSGenetics

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Comments from the reviewers (if applicable):

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Data Deposition**

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the [Dryad Digital Repository](http://www.datadryad.org). As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our [website](http://journals.plos.org/plosgenetics/s/data-availability#loc-recommended-repositories).

The following link will take you to the Dryad record for your article, so you won\'t have to re‐enter its bibliographic information, and can upload your files directly: 

<http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-19-01315R3>

More information about depositing data in Dryad is available at <http://www.datadryad.org/depositing>. If you experience any difficulties in submitting your data, please contact <help@datadryad.org> for support.

Additionally, please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Press Queries**

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper\'s publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there\'s anything the journal should know or you\'d like more information, please get in touch via <plosgenetics@plos.org>.

10.1371/journal.pgen.1008788.r008
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